Delcath Systems (NASDAQ:DCTH) Stock Crosses Above Fifty Day Moving Average – Here’s What Happened

Delcath Systems, Inc. (NASDAQ:DCTH)’s share price crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $15.53 and traded as high as $20.30. Delcath Systems shares last traded at $20.27, with a volume of 3,448,393 shares traded.

Key Headlines Impacting Delcath Systems

Here are a few of the latest headlines about DCTH:

• Positive Sentiment: Delcath reported quarterly EPS of $0.17, versus analyst expectations for a loss of $0.09, and revenue of $35.1 million, well ahead of the $26.0 million consensus estimate. The strong results helped propel shares to a 12-month high. Delcath Systems Sets New 12-Month High After Strong Earnings
• Positive Sentiment: HC Wainwright raised its price target to $36 from $32 and reaffirmed its Buy rating, signaling substantial potential upside in the firm’s view. Delcath Systems Gets a Buy from H.C. Wainwright
• Negative Sentiment: HC Wainwright trimmed its Q2 2027 EPS forecast to $0.11 from $0.12, a small near-term estimate reduction that contrasts with its higher longer-term projections.

Wall Street Analyst Weigh In

DCTH has been the subject of a number of recent research reports. Zacks Research lowered Delcath Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. HC Wainwright upped their price target on Delcath Systems from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings lowered Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. BTIG Research increased their price target on Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Monday. Finally, Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.33.

Delcath Systems Stock Performance

The stock’s 50-day simple moving average is $15.71 and its 200 day simple moving average is $12.59. The company has a market capitalization of $757.38 million, a PE ratio of 136.06 and a beta of 0.62.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.26. The business had revenue of $35.10 million for the quarter, compared to analyst estimates of $25.99 million. Delcath Systems had a net margin of 6.05% and a return on equity of 5.56%. On average, analysts expect that Delcath Systems, Inc. will post -0.17 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DCTH. Royal Bank of Canada increased its holdings in shares of Delcath Systems by 14.8% in the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock valued at $170,000 after acquiring an additional 2,364 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Delcath Systems during the second quarter worth approximately $48,000. IFP Advisors Inc purchased a new stake in Delcath Systems during the second quarter worth approximately $52,000. Alps Advisors Inc. lifted its stake in Delcath Systems by 30.3% during the third quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock worth $729,000 after purchasing an additional 10,600 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Delcath Systems by 54.0% in the first quarter. Bank of America Corp DE now owns 57,729 shares of the company’s stock valued at $536,000 after purchasing an additional 20,249 shares in the last quarter. 61.12% of the stock is owned by institutional investors and hedge funds.

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.